New 5.5 ml Syringe System Facilitates Large-Volume Doses
A new passive safety device and syringe combination may help patients manage large-volume biologic injections at home.
Updated on Oct. 1, 2026 in Diabetes
Live Poll
Do you believe self-administration technology for large-volume therapies makes at-home healthcare better?
SCHOTT Pharma and Nemera have launched a new passive safety system for 5.5 ml prefillable glass syringes. This platform is designed to support the self-administration of large-volume biologics for patients.
Why it matters
The development aims to simplify the self-injection process for complex biologic therapies. By streamlining the device platform, it seeks to reduce complexity for pharmaceutical companies and improve usability for patients.
Human factors studies validated the system for users with varying levels of dexterity, while technical verification confirmed compatibility and injection performance for the 5.5 ml platform.
The players
SCHOTT Pharma
A developer of specialized drug containment and delivery solutions for the pharmaceutical industry.
Nemera
A designer and manufacturer of drug delivery devices, including parenteral, ophthalmic, and nasal systems.
The details
The system utilizes a 5.5 ml prefillable glass syringe integrated with a passive safety device designed for subcutaneous administration. The platform features ultra-low tungsten residuals to maintain the integrity of biologic medications. The safety device operates passively, meaning the user does not need to perform extra steps to engage it, which simplifies the process for those managing their own care.
Timeline
October 6-7, 2026: Exhibition at PDA Palm Springs.
October 6-8, 2026: Exhibition at CPHI Milan.
Health Landscape
The development of these 5.5 ml syringes tracks with the wider trend of moving specialized biologic treatments from clinical settings to patient-led self-administration. This system marks a move to standardize the hardware needed for high-volume self-injections, following the broader trend of home-based biologic therapy management.
As new delivery platforms reach the market, patients using large-volume biologic therapies may find injection devices become more intuitive. If you struggle with dexterity during self-injections, it is worth discussing available delivery options and potential usability aids with your doctor.
The takeaway
Large-volume biologics are increasingly being adapted for home use through specialized delivery hardware. If you are prescribed injectable biologics, talk to your physician about the importance of device usability and how specific delivery systems might suit your daily routine.
Further reading
For more information on managing injectable treatments, see our Diabetes section.
Source note: This article includes information reported by Manufacturingchemist.
Live Poll
Do you believe self-administration technology for large-volume therapies makes at-home healthcare better?
